MCID: OCL006
MIFTS: 52

Ocular Hypertension

Categories: Eye diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 11 53 43 14 16 71 75 33
Intraocular Pressure Increase 33
Oht - [ocular Hypertension] 33
Oh - [ocular Hypertension] 33
Hypertension, Ocular 38

Classifications:



External Ids:

Disease Ontology 11 DOID:9282
ICD9CM 34 365.04
MeSH 43 D009798
NCIt 49 C3285
SNOMED-CT 68 267721003
ICD11 33 535283437
UMLS 71 C0028840

Summaries for Ocular Hypertension

Disease Ontology: 11 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary: Ocular Hypertension, also known as intraocular pressure increase, is related to open-angle glaucoma and intraocular pressure quantitative trait locus, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are Cellular responses to stimuli and Signal Transduction. The drugs Dorzolamide and Carteolol have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: 75 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 open-angle glaucoma 31.7 TMCO1 TGFB2 OPTN MYOC
2 intraocular pressure quantitative trait locus 31.6 TMCO1 TGFB2 PTGFR OPTN MYOC CA2
3 hypertension, essential 31.2 RHOA NR3C1 MTOR JUN HSD11B1 FOS
4 glaucoma, primary open angle 31.2 TMCO1 TGFB2 RHOA RHO PTGFR OPTN
5 glaucoma, normal tension 30.9 TMCO1 PTGFR OPTN MYOC
6 neovascular glaucoma 30.8 TGFB2 MYOC EPO
7 refractive error 30.8 TGFB2 RHO MYOC
8 primary angle-closure glaucoma 30.7 TMCO1 TGFB2 OPTN MYOC
9 retinal ischemia 30.7 RHO EPO AKT1
10 macular degeneration, age-related, 1 30.5 TGFB2 RLBP1 RHO MYOC AKT1
11 ocular pigment dispersion with or without glaucoma 30.4 TMCO1 MYOC
12 steroid-induced glaucoma 30.3 TGFB2 OPTN NR3C1 MYOC
13 acute closed-angle glaucoma 29.9 TMCO1 OPTN MYOC
14 chronic closed-angle glaucoma 29.9 TGFB2 MYOC
15 glaucoma 1, open angle, a 29.8 OPTN MYOC
16 exudative vitreoretinopathy 1 29.8 RHO EPO AKT1
17 juvenile glaucoma 29.6 TGFB2 OPTN MYOC
18 eye disease 29.3 TGFB2 RLBP1 RHOA RHO OPTN MYOC
19 retinitis pigmentosa 28.7 TGFB2 RLBP1 RHOA RHO OPTN MYOC
20 glaucoma 3, primary congenital, a 11.0
21 glaucoma, hereditary 11.0
22 glaucoma 3, primary infantile, b 10.9
23 glaucoma, hereditary adult type 1a 10.9
24 glaucoma, hereditary juvenile type 1b 10.9
25 glaucoma, primary infantile type 3a 10.9
26 glaucoma 1, open angle, f 10.9
27 optic nerve disease 10.6
28 uveitis 10.6
29 cataract 10.6
30 macular retinal edema 10.5
31 myopia 10.5
32 exfoliation syndrome 10.5
33 anterior uveitis 10.5
34 conjunctivitis 10.4
35 ocular hyperemia 10.4
36 retinal vein occlusion 10.4
37 retinal detachment 10.3
38 microvascular complications of diabetes 5 10.3
39 keratitis, hereditary 10.3
40 diabetic macular edema 10.3
41 solar retinopathy 10.2 RLBP1 RHO
42 retinal perforation 10.2 TGFB2 RLBP1 RHO
43 vitreous disease 10.2 TGFB2 RLBP1 RHO
44 macular dystrophy, dominant cystoid 10.2
45 skin atrophy 10.2 NR3C1 FKBP5 FKBP4
46 glaucoma, primary closed-angle 10.2
47 keratopathy 10.2
48 neuropathy 10.2
49 lens disease 10.2 TGFB2 RHO MYOC
50 allergic conjunctivitis 10.2

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 AKT1 CA2 EPO FKBP4 FKBP5 FOS
2 nervous system MP:0003631 10.39 AKT1 CA2 FKBP5 FOS HSD11B1 JUN
3 growth/size/body region MP:0005378 10.3 AKT1 CA2 FKBP4 FKBP5 FOS HSD11B1
4 endocrine/exocrine gland MP:0005379 10.21 AKT1 CA2 FKBP4 FOS HSD11B1 JUN
5 immune system MP:0005387 10.2 AKT1 CA2 EPO FOS HSD11B1 JUN
6 normal MP:0002873 10.19 AKT1 FKBP5 FOS JUN MTOR MYOC
7 cellular MP:0005384 10.18 AKT1 EPO FKBP4 FOS HSD11B1 JUN
8 renal/urinary system MP:0005367 10.1 CA2 FKBP4 FKBP5 MTOR NR3C1 RHOA
9 embryo MP:0005380 10.1 AKT1 EPO FKBP4 FKBP5 FOS JUN
10 no phenotypic analysis MP:0003012 10.07 JUN MLIP MTOR MYOC NR3C1 OPTN
11 respiratory system MP:0005388 9.91 AKT1 CA2 EPO HSD11B1 JUN MTOR
12 skeleton MP:0005390 9.85 AKT1 CA2 FOS JUN MTOR NR3C1
13 hematopoietic system MP:0005397 9.73 AKT1 EPO FOS HSD11B1 JUN MTOR
14 mortality/aging MP:0010768 9.5 AKT1 CA2 EPO FKBP4 FKBP5 FOS

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4 120279-96-1 5284549
2
Carteolol Approved Phase 4 51781-06-7 2583
3
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
4
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
5
Dipivefrin Approved Phase 4 52365-63-6 3105
6
Mitomycin Approved Phase 4 50-07-7 5746
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
9
Loteprednol etabonate Approved, Experimental Phase 4 82034-46-6, 129260-79-3 22227703 9865442 444025
10
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
11
Thymol Approved Phase 4 89-83-8 6989
12
Brinzolamide Approved Phase 4 138890-62-7 68844
13 Sympatholytics Phase 4
14 Carbonic Anhydrase Inhibitors Phase 4
15 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
16
Brimonidine Tartrate Phase 4 70359-46-5
17 Anti-Asthmatic Agents Phase 4
18 Respiratory System Agents Phase 4
19 Lubricant Eye Drops Phase 4
20 Bronchodilator Agents Phase 4
21 Anti-Allergic Agents Phase 4
22 Xhance Phase 4
23 Dermatologic Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Tobramycin, Dexamethasone Drug Combination Phase 4
26
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 3 55-56-1 2713 9552079
27
Betaxolol Approved, Investigational Phase 3 659-18-7, 63659-18-7 2369
28
Hydrocortisone succinate Approved Phase 2, Phase 3 2203-97-6 3643
29
Hydrocortisone acetate Approved, Vet_approved Phase 2, Phase 3 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 3640 5754
31
Adenosine Approved, Investigational Phase 3 58-61-7 60961
32
Apraclonidine Approved Phase 3 66711-21-5 2216
33
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
34
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
35
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
36 Anecortave Investigational Phase 2, Phase 3 10184-70-0
37 Chlorhexidine gluconate Phase 3
38 Adrenergic beta-1 Receptor Antagonists Phase 3
39 Angiogenesis Inhibitors Phase 2, Phase 3
40 Hydrocortisone 17-butyrate 21-propionate Phase 2, Phase 3
41 Anticonvulsants Phase 3
42 Vasodilator Agents Phase 3
43 Analgesics Phase 3
44 Calcium, Dietary Phase 3
45 calcium channel blockers Phase 3
46 Tocolytic Agents Phase 3
47
Calcium Nutraceutical Phase 3 7440-70-2 271
48
Acetazolamide Approved, Vet_approved Phase 2 59-66-5, 1424-27-7 1986
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
50
Nebivolol Approved, Investigational Phase 2 152520-56-4, 99200-09-6, 118457-14-0 71301

Interventional clinical trials:

(show top 50) (show all 597)
# Name Status NCT ID Phase Drugs
1 An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension. Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
2 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
3 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
4 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
5 IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
6 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
7 A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting Completed NCT03808688 Phase 4 Netarsudil Ophthalmic Solution 0.02%
8 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
9 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
10 Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
11 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
12 Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension Completed NCT00761995 Phase 4 Azopt;Cosopt
13 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%
14 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension Completed NCT02097719 Phase 4 bimatoprost 0.01%;travoprost 0.004%;timolol 0.5%;hypromellose 0.3%
15 A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
16 Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
17 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension Completed NCT00541242 Phase 4 bimatoprost 0.03% eye drops;latanoprost 0.005% eye drops
18 Intraocular Pressure and Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in Patients With Ocular Hypertension or Glaucoma: A Randomized, Single Masked, 3 Month Cross-over, Investigator Led, European Multicentre Trial (SPORT) Completed NCT01975714 Phase 4 Preservative-free latanoprost;Preservative-free bimatoprost
19 An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension Completed NCT01881126 Phase 4 bimatoprost 0.01%;travatan 0.004%;timolol 0.5%;hypromellose 0.3%
20 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
21 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
22 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance Completed NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
23 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
24 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Completed NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
25 An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects Completed NCT00811564 Phase 4 fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution;latanoprost 0.005%
26 An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® Completed NCT00799682 Phase 4 Xalatan;Travatan Z
27 A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
28 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
29 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
30 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
31 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
32 A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension Completed NCT00471380 Phase 4 travoprost 0.004% and brinzolamide 1%;fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
33 Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
34 A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension. Completed NCT00140049 Phase 4 Xalacom;Cosopt
35 Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
36 A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients Completed NCT00972426 Phase 4 carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
37 The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma. Completed NCT02338362 Phase 4 Fluticasone propionate inhaler;Saline placebo inhaler
38 An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness Completed NCT03204487 Phase 4 Tafluprost 15µg/ml
39 Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension Completed NCT01111890 Phase 4 Azarga (brinzolamide 1% / timolol 0.5%);Cosopt (dorzolamide 2% / timolol 0.5%)
40 The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
41 Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
42 A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
43 A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed NCT00061503 Phase 4 Travoprost
44 The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs. Completed NCT01655758 Phase 4 0.5% timolol;timolol-dorzolamide fixed combination;Latanoprost;Travoprost;Bimatoprost
45 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
46 A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension Completed NCT00348062 Phase 4 Bimatoprost
47 Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension Completed NCT00348023 Phase 4 Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
48 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
49 A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
50 Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


apraclonidine
Apraclonidine hydrochloride
Mannitol
Mannitol hexanitrate
MANNITOL PWDR
Urea
UREA POWDER

Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

Organs/tissues related to Ocular Hypertension:

MalaCards : Eye, Retina, Endothelial, Thyroid, Bone Marrow, Skin, Brain

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 5888)
# Title Authors PMID Year
1
Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. 53 62
20376328 2010
2
Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. 53 62
19148291 2009
3
[Expression of glucocorticoid receptors alpha and beta in mononuclear cells of peripheral blood in patients with glucocorticoid-induced ocular hypertension]. 53 62
19484926 2009
4
Aqueous humor myocilin protein levels in normal, genetic carriers, and glaucoma Beagles. 53 62
18435660 2008
5
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 53 62
17615537 2007
6
The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. 53 62
17563720 2007
7
Myocilin-associated exosomes in human ocular samples. 53 62
17094967 2007
8
Coiled-coil targeting of myocilin to intracellular membranes. 53 62
16973161 2006
9
Novel myocilin mutation in a Chinese family with juvenile-onset open-angle glaucoma. 53 62
16401791 2006
10
Characterization of rabbit myocilin: Implications for human myocilin glycosylation and signal peptide usage. 53 62
12697062 2003
11
Myocilin glaucoma. 53 62
12504739 2002
12
Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. 53 62
11815346 2002
13
Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. 53 62
11431441 2001
14
Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. 53 62
11133859 2001
15
Characterization and differential expression of a human gene family of olfactomedin-related proteins. 53 62
11006633 2000
16
Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors. 62
35799502 2023
17
Clinical patterns and risk factors in scleritis: a multicentric study in Colombia. 62
35796822 2022
18
The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension. 62
35980849 2022
19
Do motivational cards really benefit sibling screening of primary open-angle glaucoma probands? 62
36453305 2022
20
Effect of prostaglandin analogues on the biomechanical corneal properties in patients with open-angle glaucoma and ocular hypertension measured with dynamic scheimpflug analyzer. 62
35841397 2022
21
Topical prostaglandin analogue use and cystoid macular oedema following uneventful cataract surgery: a randomised control trial. 62
34045222 2022
22
Epidemiology of ectopia lentis and outcomes after surgery in a Danish population. 62
36449672 2022
23
Real world outcomes of sutureless and glueless sclerally fixated intraocular lens implantation. 62
34980895 2022
24
Ocular hypertension in patients with active thyroid-associated orbitopathy: a predictor of disease severity, particularly of extraocular muscle enlargement. 62
35834036 2022
25
Decreased outflow facility and Schlemm's canal defects in a mouse model of glaucoma. 62
36152913 2022
26
Microglia depletion exacerbates retinal ganglion cell loss in a mouse model of glaucoma. 62
36206859 2022
27
The Effect of Prostaglandin Analogues on Central Corneal Thickness of Patients with Glaucoma or Ocular Hypertension: a systematic review. 62
36455536 2022
28
Increased Risk of Ocular Hypertension in Patients With Cushing's Disease. 62
35980841 2022
29
Optic Disc Drusen in Patients With Ocular Hypertension: A Case Series and Review of the Literature. 62
35916300 2022
30
Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. 62
36474156 2022
31
Impairments of retinal hemodynamics and oxygen metrics in ocular hypertension-induced ischemia-reperfusion. 62
36252653 2022
32
Letter to the Editor: Association of Metabolic Syndrome With Glaucoma and Ocular Hypertension in a Midwest United States Population. 62
36223295 2022
33
Response to Letter to the Editor: Association of Metabolic Syndrome With Glaucoma and Ocular Hypertension in a Midwest United States Population. 62
36223292 2022
34
Astrocyte polarization in glaucoma: a new opportunity. 62
35662185 2022
35
Sustained release of brimonidine from [email protected]@TPU implant for treatment of glaucoma. 62
35174743 2022
36
Protocol for laser-induced chronic ocular hypertension and intracameral injection in nonhuman primates. 62
36340883 2022
37
Machine-Identified Patterns of Visual Field Loss and an Association with Rapid Progression in the Ocular Hypertension Treatment Study. 62
35817199 2022
38
Nobiletin protects retinal ganglion cells in models of ocular hypertension in vivo and hypoxia in vitro. 62
35804043 2022
39
A Novel and Reversible Experimental Primate Ocular Hypertension Model: Blocking Schlemm's Canal. 62
36380650 2022
40
Sphingomyelinases in retinas and optic nerve heads: Effects of ocular hypertension and ischemia. 62
36122624 2022
41
Effect of topical nitric oxide donors 0.03% nitroglycerin and 0.1% hydralazine on intraocular pressure in healthy canine eyes. 62
36137290 2022
42
Estimation of the intraoperative blood loss in dogs undergoing enucleation. 62
36322454 2022
43
Sympathetic activation leads to Schlemm's canal expansion via increasing vasoactive intestinal polypeptide secretion from trabecular meshwork. 62
36049555 2022
44
Stress induced aging in mouse eye. 62
36397653 2022
45
Changes in Intraocular Pressure following Narcosis With Medetomidine, Midazolam, and Fentanyl in Association With Initial Intraocular Pressure in Mice. 62
35943353 2022
46
Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension. 62
36370233 2022
47
Potential for Collider Bias in Studies Examining the Association of Central Corneal Thickness With Glaucoma. 62
36322067 2022
48
Endocyclophotocoagulation by pars plana approach in the management of refractory glaucoma with prior phacoemulsification and Ahmed gonioimplantation in a dog. 62
36321590 2022
49
Suprachoroidal injection of polyzwitterion hydrogel for treating glaucoma. 62
36279749 2022
50
Use of selective laser trabeculoplasty as an alternative in patients who developed ocular hypertension after intravitreal dexamethasone implants: a series of 35 eyes. 62
35665853 2022

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 NR3C1 MTOR JUN FOS FKBP5 FKBP4
2 13.38 TGFB2 RHOA RHO PTGFR OPTN NR3C1
3
Show member pathways
13.04 TGFB2 RHOA MTOR JUN FOS AKT1
4
Show member pathways
12.92 TGFB2 RHOA JUN FOS AKT1
5
Show member pathways
12.89 MTOR JUN FOS EPO AKT1
6
Show member pathways
12.87 TGFB2 RHOA MTOR JUN AKT1
7
Show member pathways
12.66 TGFB2 RHOA MTOR JUN FOS AKT1
8
Show member pathways
12.52 MTOR JUN FOS AKT1
9
Show member pathways
12.46 MTOR JUN FOS AKT1
10
Show member pathways
12.46 RHOA MTOR JUN FOS AKT1
11
Show member pathways
12.44 RHOA JUN FOS AKT1
12 12.43 RHOA JUN FOS AKT1
13
Show member pathways
12.42 RHOA JUN FOS AKT1
14 12.41 TGFB2 JUN FOS AKT1
15
Show member pathways
12.4 RHOA JUN FOS AKT1
16
Show member pathways
12.39 TGFB2 RHOA MTOR JUN FOS
17
Show member pathways
12.37 TGFB2 NR3C1 JUN FOS
18
Show member pathways
12.31 MTOR JUN FOS AKT1
19
Show member pathways
12.25 RHO JUN FOS AKT1
20
Show member pathways
12.22 AKT1 FOS JUN MTOR RHOA
21
Show member pathways
12.13 MTOR JUN FOS AKT1
22 12.13 RHO MTOR JUN AKT1
23
Show member pathways
12.01 RHOA MTOR JUN FOS
24
Show member pathways
11.97 MTOR JUN FOS
25 11.96 AKT1 FOS JUN RHOA
26 11.87 AKT1 FOS RHOA
27
Show member pathways
11.85 AKT1 FOS JUN MTOR RHOA
28 11.83 TGFB2 MTOR AKT1
29 11.75 AKT1 FKBP5 MTOR
30 11.73 NR3C1 JUN FOS AKT1
31 11.72 MTOR JUN FOS
32 11.72 NR3C1 JUN FOS
33
Show member pathways
11.69 RHOA JUN AKT1
34 11.68 RHOA JUN AKT1
35 11.68 JUN FOS AKT1
36 11.68 RHOA MTOR JUN AKT1
37
Show member pathways
11.66 NR3C1 JUN FOS
38
Show member pathways
11.65 FOS NR3C1 RHOA
39 11.64 MTOR JUN FOS AKT1
40 11.61 TGFB2 JUN FOS
41 11.61 JUN FOS EPO AKT1
42
Show member pathways
11.6 TGFB2 JUN FOS AKT1
43
Show member pathways
11.58 NR3C1 JUN AKT1
44 11.58 JUN FOS AKT1
45 11.56 RHOA JUN AKT1
46 11.48 AKT1 FOS JUN
47 11.43 RHOA JUN FOS AKT1
48
Show member pathways
11.4 RHOA CA2 AKT1
49 11.39 MTOR JUN AKT1
50 11.39 NR3C1 JUN FOS CA2

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 8.92 FOS JUN

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of stress fiber assembly GO:0051496 9.88 RHOA MYOC MTOR
2 positive regulation of neuron apoptotic process GO:0043525 9.85 TGFB2 RHOA NR3C1
3 cellular response to reactive oxygen species GO:0034614 9.73 JUN FOS AKT1
4 cellular response to cadmium ion GO:0071276 9.63 AKT1 FOS JUN
5 heart valve morphogenesis GO:0003179 9.62 TGFB2 MTOR
6 positive regulation of cell growth GO:0030307 9.56 TGFB2 RHOA MTOR AKT1
7 positive regulation of miRNA transcription GO:1902895 9.23 TGFB2 NR3C1 JUN FOS

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 11-cis retinal binding GO:0005502 8.92 RLBP1 RHO

Sources for Ocular Hypertension

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....